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Abstract
Objective To prospectively evaluate the diagnostic accura-
cy of whole-body T2-weighted (wbT2), whole-body
diffusion-weighted imaging (wbDWI) and wbT2/wbDWI
image fusion for malignant tumour detection compared
with PET/CT.
Methods Sixty-eight patients (44 men; 60±14 years) under-
went PET/CT for staging of malignancy and were consecu-
tively examined by 1.5-Tesla MRI including wbT2 and
wbDWI. Two radiologists independently assessed wbDWI,
wbT2, wbT2 + wbDWI (side-by-side) and wbT2 + wbDWI +
wbT2/wbDWI image fusion for the presence of malignancy.
PET/CT served as a reference standard.
Results PET/CT revealed 374 malignant lesions in 48/64
(75%) patients. Detection rates and positive predictive
value (PPV) of wbT2 and wbDWI alone were 64% and
84%, and 57% and 93%, respectively. Detection rates and
PPVof wbT2 and wbDWI for side-by-side analysis without
and with fused images were 72% and 89%, and 74% and
91%, respectively. The detection rate was significantly
higher with side-by-side analysis and fused image analysis
compared with wbT2 and wbDWI alone (p=.0159;
p<.0001). There was no significant difference between
fused image interpretation and side-by-side analysis.
Conclusions WbDWI allows detection of malignant lesions
with a similar detection rate to wbT2. Side-by-side analysis
of wbT2 and wbDWI significantly improves the overall
detection rate and fused image data provides no added
value.
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Introduction
Integrated positron emission tomography (PET)/computed
tomography (CT) plays a central role in medical imaging
for detection and staging of cancer [1, 2].
Over the past decade whole-body magnetic resonance
imaging (MRI) has become applicable for evaluation of
malignancy because of advances in imaging technology
[3, 4]. Whole-body T2-weighted imaging (wbT2) with fat
suppression and short tau inversion recovery (STIR)
demonstrate the most frequently applied sequences be-
cause of good anatomical image information [5]. Com-
pared with PET/CT, however, assessment of malignant
tumour disease with MRI is mainly based on morpholog-
ical changes [6], whereas functional changes are not be
visualised.
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Integration of functional data in terms of whole-body
(wb) diffusion-weighted imaging (DWI) was first enabled
by Takahara et al. [7], who developed wbDWI under free
breathing (whole-body diffusion-weighted imaging with
background body signal suppression; DWIBS). As most
tumours are not only characterised by pathological glucose
metabolism but also restricted diffusion because of higher
tissue cellularity [8], wbDWI can be useful in the detection
of malignancy similar to PET imaging [9]. However,
wbDWI is accompanied by low spatial-resolution and
therefore restricted anatomical information [10]. Similar to
PET/CT imaging, where CT provides detailed morpholog-
ical information that increases diagnostic accuracy com-
pared with PET alone [11], combined assessment of wbT2
and wbDWI may improve evaluation of malignant tumour
disease [12].
The aim of this study was to evaluate the ability of wbT2
and wbDWI for the detection of malignant tumours and to
evaluate the additional value of wbT2/wbDWI image
fusion.
Materials and methods
Patients
This prospective study was approved by the local ethics
committee. Written informed consent was obtained from all
patients according to the Declaration of Helsinki guidelines.
Between January and November 2009, 68 patients with
malignancies (44 men; 24 women; mean age 60±14 years),
who were referred for staging of malignant tumour disease
by means of PET/CT for clinical reasons, consecutively
underwent an additional wbT2 and wbDWI examination.
WbT2 and wbDWI was performed within 10 days before or
after PET/CT.
Exclusion criteria were chemotherapy and radiothera-
py between PET/CT and MRI, and denied informed
consent (n=0) as well as MRI-related contraindications
(i.e. claustrophobia or metallic implants).
Four patients were excluded because of chemotherapy
(n=3) and combined radio-/chemotherapy (n=1) between
the two examinations. Thus, the study was conducted in
64 patients, 42 men (mean age, 60±13 years; range, 18–
80 years) and 22 women (mean age, 59±17 years; range,
20–78 years), with a overall mean age of 60±14 years;
range 18–80 years.
Underlying tumour disease was oesophagogastrointesti-
nal carcinoma in 31 patients (48%), cholangiocarcinoma in
14 patients (22%), lymphoma in 11 patients (17%),
pancreatic carcinoma in five patients (8%) and melanoma
in three patients (5%). Eighteen patients (28%) underwent
chemotherapy, six patients (9%) combined chemo- and
radiotherapy, and one patient had radiotherapy (2%) before
the imaging protocol, respectively (Table 1).
PET/CT imaging
Imaging with PET/CT was acquired using [18]F-fluoro-
deoxyglucose (18F-FDG) on a combined PET-CT in-line
system (Discovery VCT; GE HealthCare, Waukesha, WI,
USA). 18F-FDG (350 MBq) was injected 60 min before
PET imaging when glucose levels were within the normal
range (range, 80–120 mg/dL [4.4–6.7 mmol/L]) after at
least 4 h of fasting. Whole-body (head to knee) low-dose
CT for attenuation correction was performed with acquisi-
tion parameters of 40 mAs, 140 kV, 0.5 s/ rotation, 4.25-
mm slice thickness, 867-mm mean image length, pitch of
1.7, and 22.5-s data acquisition time. Emission PET was
acquired within 1 min of CT with the patient in the same
position using 8–9 incremental table positions from head to
knees and a matrix of 128×128. In 20/68 (29%) of the
patients an additional, clinically indicated, abdominal
contrast-enhanced CT was performed after injection of
100 mL of iopromide intravenous contrast agent (Visipac
320, iodum 320 mg/mL Sinclair & Rush, Inc., MO, USA)
followed by 20 mL saline solution. Imaging parameters
were 120 kV, 100–200 mAs attenuation-based tube current
modulation (auto mAs), a slice thickness of 3.75 mm and a
Table 1 Patient demographics
Male patients 42 (66%)
Female patients 22 (34%)
Age (years) 60±14 (18–80)
Primary malignancy
Oesophagogastrointestinal cancer 31 (48%)
Oesophageal carcinoma 9 (14%)
Gastric carcinoma 7 (11%)
Colorectal carcinoma 15 (23%)
Cholangiocellular carcinoma 14 (22%)
Lymphoma 11 (17%)
Hodgkin lymphoma 2 (18%)
B-cell lymphoma 6 (55%)
T-cell lymphoma 3 (27%)
Pancreatic carcinoma 5 (8%)
Melanoma 3 (5%)
Medical history
Primary staging 45 (70%)
Resected primary malignancy 14 (22%)
Re-staging after therapy 19 (30%)
Chemotherapy 18 (28%)
Radiotherapy 1 (2%)
Combined radio-/Chemotherapy 6 (9%)
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pitch of 1.7. The total average imaging time for PET/CT
was 28±6 min.
Magnetic resonance imaging
All patients underwent MRI at 1.5-T (Signa Echospeed
EXCITE HDx, GE Healthcare, Waukesha, WI, USA) in a
supine position with arms overhead or if not possible
parallel to the body and feet first. For signal detection of the
head and lower extremity the integrated scanner coil was
used, whereas thorax and abdomen were covered through
an eight-element body phased-array coil allowing for
parallel imaging. Overview and calibration MR images
for surface-coil sensitivity as well as calibration imaging for
upper and lower body-array coils were acquired in
expiration.
WbDWI was performed under free breathing using an
axial single-shot echo planar imaging sequence and motion
probing gradients in superior/inferior direction with b-
values of 0 and 700 s/mm2 for background body signal
suppression. For fat suppression a chemical shift selective
saturation pulse (“fat-sat”) was used. WbDWI parameters:
Repetition time (TR)/Echo Time (TE): 6200/68.6 msec;
image matrix: 128×128; field of view: 480×432 mm
(axial); slice thickness: 7 mm; spacing: 1 mm; number of
excitations (NEX): 6. The total average imaging time for
WbDWI was 22±2 min.
WbT2 was acquired corresponding to each wbDWI
section using an axial steady state free precession gradient
echo sequence (fast imaging employing steady state
acquisition; FIESTA) with breathing triggering in thorax
and abdomen. WbT2 parameters: TR/TE: 4.4/2.0 ms,
inversion time: 200 ms; image matrix: 288×256; field of
view: 480×432 mm (axial); slice thickness: 7 mm; spacing:
1 mm; NEX: 1. Total average imaging time for wbT2 was
19±2 min.
Image post-processing
All MRI and PET/CT images were interpreted at a standard
workstation (AW4.3; GE Medical Systems). DWI data were
separated with two different b-values (b = 0 s/mm2; b =
700 s/mm2) yielding 2×7 datasets for each patient.
Afterwards, T2 and DWI datasets were reformatted to a
whole body image (wbT2 and wbDWI) eliminating the
overlaps between sets performed by an investigator who
was not involved in data analysis. Apparent diffusion
coefficient (ADC) maps were generated.
For image registration and fusion a software prototype
(“Multimodality”, AW4.3; GE Healthcare) was used to fuse
the wbT2 and the b = 700 s/mm2 wbDWI images. This
software enables automatic propagation of rigid registration
across series acquired in the same examination based on
three registration methods: automatic, manual and
landmark-based. In our study, wbT2 and the b = 700 s/
mm2 wbDWI images were fused automatically because of
co-registered acquisition of wbT2 and wbDWI source
images. WbDWI data image information was displayed on
the fused images in an inverted colour scale equal to that
used for PET/CT fusion.
Data analysis
PET/CT
Image interpretation was performed in consensus by two
radiologists experienced in nuclear oncology body imaging.
Both readers were blinded to MRI results. Attenuation-
corrected PET images, low-dose CT images, and co-
registered fused images were displayed and analysed
together. If available, contrast-enhanced CT was included
in PET/CT analysis. Malignant lesions were diagnosed
when abnormal focal FDG-uptake, observed on PET
images corresponded to an abnormal mass on CT. Abnor-
mal focal FDG uptake was considered a FDG uptake higher
than two times the mean liver standard uptake value in the
right hepatic lobe, which was determined normal back-
ground 18F-FDG activity. In case of diffuse abnormal liver
uptake, left ventricular blood pool was used as a reference.
Pathologic FDG uptake without corresponding CT abnor-
mality was considered as malignant lesion if lesion size was
greater 2 cm in diameter for accurate measurement or, for
smaller lesions, if any other reasons like artefacts or focal
inflammation could be ruled out as reason for abnormal
FDG-uptake [13]. Lymph nodes with increased glucose
uptake were deemed positive for metastatic spread even if
they were smaller than 1 cm in short-axis diameter.
Conversely, lymph nodes with no detectable tracer uptake
were deemed negative for metastatic spread, even if they
were larger than 1 cm in the short-axis diameter. Lung
lesions were considered malignant because of morpholog-
ical issues used in daily routine even though no increased
glucose uptake was present.
Magnetic resonance imaging
Two other independent radiologists, not involved in PET/CT
data evaluation, performed image interpretation prospectively.
Both readers were blinded to PET/CT results as well as all
clinical information except the origin of the primary tumour.
In the first session, readers interpreted wbDWI alone. In the
second reading session after 10–14 days, wbT2 datasets were
interpreted alone. In the third reading session after another 10–
14 days wbT2 + wbDWI (side-by-side) datasets were
analysed. All images, including fused images were evaluated
together (wbT2 + wbDWI + wbT2/wbDWI fused images) in a
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fourth reading session after another 10–14 days. Reading
order of datasets was randomised. Concerning cases of
disagreement, a consensus reading of both readers by
discussion was appended 7 days after the initial data read-
out. WbDWI images were interpreted using the mulitplanar
reformation tool (“reformat”) allowing the assessment of axial
source images. Nomaximum intensity projection images were
evaluated. WbT2 and fused images were analysed in axial
plane using the viewer function of the AW4.3. Malignant
lesions were documented according to their exact anatomical
location and slice position for each image.
wbDWI
For wbDWI any distinct focus on b = 700 s/mm2 images
with increased signal intensity compared with the intensity
of the surrounding tissue was considered a malignant
lesion, if ADC values of the lesion were lower than ADC
values of the healthy surrounding tissue. If ADC values
were equal or greater than the surrounding tissue indicating
a T2-shine through effect, lesions were considered benign.
Accordingly lymph nodes were considered malignant if
ADC values showed restricted or increased diffusion
regardless of their size and morphology [14].
wbT2
Any lesion was classified as malignant if an intermediate to
hyperintense signal intensity in comparison to skeletal
muscle and an expansive growth pattern was present [15]
except tumorous lesions in melanoma patients, which were
also considered malignant if a hypointense signal was
present. Enlarged lymph nodes were considered to be
malignant based on measurement of the short axis diameter
with cut-off values of >10 mm for cervical, mediastinal and
retroperitoneal lymph nodes, >8 mm for intraperitoneal
lymph nodes, >11 mm for pelvic lymph nodes and >12 mm
for inguinal lymph nodes [16, 17].
Side-by-side analysis and fused images
Side-by-side analysis and interpretation of fused images
consisted of a combination of wbT2 and wbDWI evalua-
tion. Lesions were rated as malignant according to the
morphological features on wbT2 and to the functional
features on wbDWI as mentioned above. Any lesion was
rated as positive for malignancy, if the lesion was
interpreted as malignant in one of the two sequences.
Statistical analysis
Variables were described as mean±standard deviation or as
frequencies and percentages.
Inter-observer agreement was assessed by using k
statistics and interpreted as follows: A k-value greater than
0.81 corresponded to very good agreement, a k-value of
0.61 to 0.80 corresponded to good interobserver agreement,
a k-value of 0.41 to 0.60 corresponded to moderate
interobserver agreement, and a k-value of 0.21 to 0.40
corresponded to poor interobserver agreement. McNemar’s
test was used to test for significant differences in rates of
immediate interobserver agreement achieved by different
dataset evaluations.
Data of the consensus readings was used to evaluate
lesion-based detection rates as well as patient-based
diagnostic accuracy for wbT2 and wbDWI alone as well
as for side-by-side analysis and fused images. For lesion-
based analysis, detected lesions were classified as being
in the lymph nodes, liver, and lung reflecting the major
sites of malignancy. All lesions detected outside those
locations were summarised as “others” and evaluated
separately.
Detection rates as well as patient-based sensitivity,
specificity and accuracy were calculated from χ2 tests of
contingency, and 95% confidence intervals (CI) were
calculated from binomial expression.
McNemar’s test was used to test for significant differ-
ences in lesion-based detection rates and patient-based
diagnostic accuracy. P values <0.05 were considered
statistically significant for all tests. All statistical analyses
were performed using commercially available software
(SPSS, release 17.0, Chicago, IL, USA).
Results
Patients
All patients underwent MRI as well as PET/CT without
adverse events. MRI in the supine position with the arms
overhead was tolerated by 33 of 64 (52%) patients, whereas
31 of 64 (48%) did not tolerate the overhead position and
the arms had to be placed parallel to the body. In PET/CT
all patients (64/64; 100%) tolerated the examination with
their arms in the overhead position. Diagnostic image
quality was achieved in all patients for wbDWI, wbT2 ,
fused images, and PET/CT (Figs. 1, 2).
PET/CT
In total, PET/CT revealed 374 malignant lesions in 48/64
(75%) patients. Most malignant lesions were detected in
lymph nodes (n=153), liver (n=107) and lung (n=72).
Forty-two lesions were present in “other” locations includ-
ing soft tissue (n=11), bone (n=11), gastrointestinal tract
(n=6), kidneys (n=4), central nervous system (n=4),
pancreas (n=2), spleen (n=2) and adrenal glands (n=2).
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wbDWI
Inter-observer agreement for analysis of wbDWI was good
(k=0.75).
Overall wbDWI detected 238/374 (64%) malignant
lesions. Detection rates yielded 109/153 (71%) malignant
lymph nodes, 98/107 (92%) liver lesions, 14/72 (19%) lung
lesions, and 17/42 (40%) “other” lesions (Table 2). 46/284
(16%) lesions were regarded as false-positive lesions.
Patient based diagnostic accuracy of wbDWI for
detection of malignant lesions yielded a sensitivity of 88%
(95% CI: 77–97; 42/48), a specificity of 69% (95% CI: 42–
94; 11/16), and an accuracy of 83% (95% CI: 72–92; 53/
64) using PET/CT as a reference standard (Table 3).
wbT2
Inter-observer agreement for analysis of wbT2 was very
good (k=0.84) and significant better than with wbDWI
(p<.0001).
In total, wbT2 detected 213/374 (57%) malignant lesions
including 99/153 (65%) lymph nodes, 82/107 (77%) liver
lesions, 14/72 (19%) lung lesions, and 18/42 (43%) “other”
lesions (Table 2). 17/230 (7%) lesions were regarded as
false-positive lesions. No significant difference was ob-
served in overall detection rate between wbT2 and wbDWI
(p=.07). Diagnostic accuracy of wbT2 for detection of
malignant lesions per patient yielded a sensitivity of 85%
(95% CI: 74–96; 41/48), a specificity of 88% (95% CI: 68–
100; 14/16), and an accuracy of 86% (95% CI: 76–95; 55/
64; Table 3) using PET/CT as a reference standard. No
significant difference compared to wbDWI (p=.99) was
present.
Side-by-side analysis
Inter-observer agreement for side-by-side analysis of wbT2
and wbDWI was very good (k=0.83) with no significant
difference to wbT2 (p=.40) but significant difference to
wbDWI (p<.0001)
Fig. 1 A 74-year-old male
patient with brain metastases
from a melanoma. WbDWI (a)
and wbT2 (b) images showed
the tumour in the left frontal
lobe. Additionally, fused image
(c) data interpretation allowed
the detection of this lesion
compared to the PET/CT images
(d) which served as the
reference standard
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Side-by-side analysis yielded a total of 270/374 (72%)
malignant lesions including 125/153 (82%) malignant
lymph nodes, 97/107 (91%) liver lesions, 24/72 (33%)
lung lesions, and 24/42 (57%) “other” lesions (Table 2). 32/
302 (11%) lesions were regarded as false-positive lesions.
Overall detection rate of side-by-side analysis was signif-
Detection rate Positive predictive value
wbDWI 63.6% (58–68;238/374) 83.8% (79–88;238/284)
Lymph node 71.2% (63–78;109/153) 85.8% (79–92;109/127)
Liver 91.5% (85–97;98/107) 86.7% (80–93;98/113)
Lung 19.4% (9–29;14/72) 93.3% (77–100;14/15)
Other 40.4% (24–56;17/42) 58.6% (38–78;17/29)
wbT2 56.9% (51–62;213/374) 92.6% (89–96;213/230)
Lymph node 64.7% (56–72;99/153) 93.3% (88–98;99/106)
Liver 76.6% (68–85;82/107) 90.1% (83–96;82/91)
Lung 19.4% (9–29;14/72) 100% (96–100;14/14)
Other 42.8% (26–59;18/42) 94.7% (82–100;18/19)
Side-by-side* 72.1% (67–76;270/374) 89.4% (85–93;270/302)
Lymph node 81.6% (75–88;125/153) 92.5% (87–97;125/135)
Liver 90.6% (84–96;97/107) 85.8% (78–92;97/113)
Lung 33.3% (21–44;24/72) 96% (86–100;24/25)
Other 57.1% (40–73;24/42) 82.7% (67–98;24/29)
Fused images** 73.5% (68–78;275/374) 90.7% (87–94;275/303)
Lymph node 84.3% (78–90;129/153) 95.5% (91–99;129/135)
Liver 90.6% (84–96;97/107) 84.3% (77–91;97/115)
Lung 34.7% (23–46;25/72) 96.1% (86–100;25/26)
Other 57.1% (40–73;24/42) 88.8% (75–100;24/27)
Table 2 Lesion-based diagnos-
tic accuracy for detection of
malignant lesions using PET/CT
as the reference standard
*Significant difference com-
pared with both wbDWI (p<
0.05) and wbT2 (p<0.0001);
**significant difference com-
pared with both wbDWI (p<
0.001) and wbT2 (p<0.0001)
Numbers in parentheses are 95%
confidence intervals and abso-
lute numbers
wbDWI whole-body diffusion-
we igh ted Imaging , wbT2
whole-body T2-weighted Imag-
ing, side-by-side: wbDWI +
wbT2; fused images: wbDWI +
wbT2 + wbDWI/wbT2 fused
images
Other: intestinal and urogenital
tract, spleen, soft tissue, skeletal
system, central nervous system
Fig. 2 A 35-year-old male pa-
tient with retroperitoneal lymph
node metastases from colorectal
cancer. a WbDWI correctly
depicted three retroperitoneal
lymph node metastases
(arrows). b WbT2 also depicted
the two para-aortic lymph node
metastases and the enlarged
lymph node dorsal to the pan-
creatic head (arrows). Both side-
by-side analysis (a+b) and im-
age fusion (c) allow compre-
hensive assessment of tumour
spread in comparison to PET/CT
(d)
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icant higher compared to both wbDWI (p<.05) and wbT2
(p<.0001) (Figs. 3, 4).
Diagnostic accuracy of side-by-side analysis on a per
patient basis showed a sensitivity of 96% (95% CI: 89–100;
46/48), a specificity of 75% (95% CI: 50–99; 12/16), and
an accuracy of 91% (95% CI: 82–98; 58/64, Table 3) using
PET/CT as a reference standard. Regarding diagnostic
accuracies, there were neither significant differences be-
tween side-by-side and wbT2 (p=.42) nor between side-by-
side and wbDWI (p=.30), respectively.
Fused images
Inter-observer agreement for analysis of fused images was
very good (k=0.83) with no significant difference to both
wbT2 and side-by-side analysis.
Assessment of fused images revealed a total of 275/374
(74%) malignant lesions including 129/153 (84%) lymph
nodes, 97/107 (91%) liver lesions, 25/72 (35%) lung
lesions, and 24/42 (57%) “other” lesions (Table 2). 28/303
(9%) lesions were regarded as false-positive lesions. No
significant difference was observed regarding the overall
detection rate as compared to side-by-side analysis (p=.73).
However, significant differences were still evident as
compared to solely using wbDWI (p=.01) and wbT2
images (p=.0001), respectively.
Patient based diagnostic accuracy of fused images
was similar to side-by-side analysis and yielded a
sensitivity of 96% (95% CI: 89–100; 46/48), a speci-
ficity of 75% (95% CI: 50–99; 12/16), and an accuracy
of 91% (95% CI: 82–98; 58/64, Table 3) using PET/CT
as a reference standard. Fused images did not improve
Table 3 Patient-based diagnostic accuracy for detection of malignant lesions using PET/CT as the reference standard
Diagnostic accuracy
Sensitivity (%) Specifity (%) Accuracy (%)
wbDWI 88% (77–97;42/48) 69% (42–94;11/16) 83% (72–92;53/64)
wbT2 85% (74–96;41/48) 81% (58–100;13/16) 84% (74–94;54/64)
Side-by-side 96% (89–100;46/48) 75% (50–99;12/16) 91% (82–98;58/64)
Fused images 96% (89–100;46/48) 75% (50–99;12/16) 91% (82–98;58/64)
Numbers in parentheses are 95% confidence intervals and absolute numbers; wbDWI whole-body diffusion-weighted Imaging, wbT2 whole-body
T2-weighted Imaging, side-by-side: wbDWI + wbT2; fused images: wbDWI + wbT2 + wbDWI/wbT2 fused images
Fig. 3 A 59-year-old female
patient with retroperitoneal
lymph node metastases from
cholangiocarcinoma. a WbDWI
showed a hyperintense lesion
(arrow) in the right lower
abdomen that was missed by
both investigators. b Interpreta-
tion of wbT2 alone did not
allow correct lesion detection.
Both side-by-side analysis (a+b)
and image fusion (c) correctly
depicted the malignant lymph
node metastases in comparison
to PET/CT (d)
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(p=.76) the diagnostic accuracy as compared to side-by-
side analysis.
Discussion
The results presented herein indicate that wbDWI allows
detection of malignant lesions with similar accuracy to
wbT2. Side-by-side analysis significantly improved the
overall detection rate compared with the evaluation of
wbT2 and wbDWI images separately. Additional assess-
ment of fused images showed no significant improvement
compared with side-by-side analysis for both lesion-based
and patient-based assessment.
Concerning wbDWI, there was an overall detection rate of
64% and a patient-based diagnostic accuracy of 82%, which is
consistent with recent studies evaluating detection of non-
small cell lung cancer metastases [18] or breast cancer [19].
Other studies showed a higher diagnostic performance using
DWI for distinct tumour entities like colorectal and pancre-
atic adenocarcinoma [20, 21] or endometrial cancer [22],
which might be due to the use of organ-specific protocols
compared with a wbDWI protocol. Lymph nodes accounted
for many false-positive lesions in wbDWI. This may be
attributable to the generally high signal intensity of lymph
nodes in DWI and the lack of standardisation in lymph node
interpretation using DWI [23]. We evaluated lymph nodes by
comparing the relative signal intensity of suspect nodes with
that of certainly benign lymph nodes as previously recom-
mended [14]. Various other attempts however have been
made for diffusion-weighted imaging as regards lymph node
evaluation using visual assessment [24], size measurements
[25] and absolute ADC measurements [26].
WbT2, derived from FIESTA, yielded a detection rate of
57% with a high PPV (93%), which is comparable to the
diagnostic accuracy of other T2-weighted whole-body
sequences like STIR [3, 27]. Our findings extend the
findings of Bhosale et al. [28] who have already demon-
strated the feasibility of FIESTA for oncological body
imaging. Furthermore, this was performed without the use
of contrast media, which has also been proposed for whole-
body imaging to evaluate malignancy [5, 29].
In our study, the detection rate for malignant liver lesions
was lower for wbT2 than for wbDWI. This reflects the
findings of a study showing that DWI is more sensitive than
T2-weighted imaging for the detection of hepatic metasta-
ses [30]. On the other hand, wbDWI showed a low PPV of
86.7% compared with wbT2, which may be caused through
either incorrect lesion localisation due to limited spatial
resolution of wbDWI or T2-shine-through effects. Most
false-negative results were accounted for by lung metasta-
ses in both wbT2 and wbDWI, which indicates a limited
capability for metastases detection in the lung and probably
reflects the advantage of CT within PET/CT.
Side-by-side analysis improved the overall detection rate
significantly instead of analysing wbT2 and wbDWI
images separately, thus underlining the incremental value
of the combined image interpretation. This is consistent
with a study showing a significant increase in diagnostic
Fig. 4 A 69-year-old male
patient with metastases in the rib
from colorectal cancer. WbDWI
(a), wbT2(b), and fused images
(c) showed no evidence of
malignant lesion. This lesion
was missed on wbDWI, wbT2,
and fused images. The reference
standard PET/CT showed clear
FDG-uptake in a left anterior rib
consistent with an osseous
metastasis (d)
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accuracy for detection of small cell lung cancer metastases
when adding anatomical whole-body MRI sequences to
wbDWI [18]. There is also evidence of an increased overall
accuracy evaluating local malignant tumour spread in
urinary bladder cancer for side-by-side analysis compared
with interpretation of DWI and T2-weighted images alone
[31]. Our results may carry forward those experiences from
local tumour analysis to whole-body imaging.
WbT2/wbDWI image fusion shows significantly higher
detection rates compared with wbT2 and wbDWI alone,
which parallels findings from retrospective image fusion
studies of DWI and T2-weighted image data [31–33].
However, these studies did not evaluate side-by-side
analysis. In our patient cohort, the addition of fused images
could not improve detection rates when compared with
side-by-side assessment alone. Experiences from PET/CT
fusion have shown an additional value of fused image data
in comparison to side-by-side analysis [34, 35]. The fact,
that we did not demonstrate a significant diagnostic
improvement by image fusion might be due to the better
spatial resolution of wbDWI at b-value 700 s/mm2
compared with the spatial resolution of PET.
Study limitations
We did not use a b-value of 1,000 s/mm2, which is the most
common b-value for wbDWI and might yield superior body
background suppression compared with a b-value of 700 s/
mm2. However, the use of a lower b-value yields a superior
signal to noise ratio and spatial resolution and might
therefore be advantageous in detecting small lesions. We
did not perform cardiac triggering or respiratory triggering
for wbDWI (which may have reduced signal loss and image
blurring, respectively) limiting evaluation of the left hepatic
lobe, the mediastinum and the lung [10]. WbDWI image
slices were relatively thick (7 mm) with 1 mm gaps . We
evaluated a heterogeneous patient population with different
malignancies in this study; the population may also have a
selection bias due to the distribution of malignancies. We
investigated tumour detection using relative ADC measure-
ments and did not use absolute ADC measurements for
tumour characterisation. We used a built-in body coil for
the head, neck and lower extremity with inferior contrast-
to-noise ratio compared with a surface coil. PET/CT was
used as a reference standard comprising limitations for
detection of distinct tumour entities itself.
Conclusion
Using PET/CT as reference standard, wbDWI allows
detection of malignant lesions with a similar detection rate
to wbT2. Side-by-side analysis of wbT2 and wbDWI
significantly improves the overall detection rate and fused
image data interpretation provides no added value.
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